Trust Company of Vermont’s Jazz Pharmaceuticals JAZZ Stock Holding History

Trust Company of Vermont’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-85	Closed	-$12.4K	–	874
2023 Q1	$12.4K	Hold	85	–	–	﹤0.01%	673
2022 Q4	$13.5K	Hold	85	–	–	﹤0.01%	640
2022 Q3	$11K	Hold	85	–	–	﹤0.01%	701
2022 Q2	$13K	Buy	+85	New	+$13.1K	﹤0.01%	643
2020 Q1	–	Sell	-10	Closed	-$1K	–	912
2019 Q4	$1K	Buy	+10	New	+$1.36K	﹤0.01%	903
2014 Q3	–	Sell	-100	Closed	-$15K	–	805
2014 Q2	$15K	Hold	100	–	–	﹤0.01%	569
2014 Q1	$14K	Buy	+100	New	+$15.1K	﹤0.01%	575

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Trust Company of Vermont's JAZZ Position: Q2 2023 in Review

Trust Company of Vermont sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 85 shares — an estimated $12.4K sold.

Trust Company of Vermont first reported a position in JAZZ in Q1 2014 and held it in 7 quarters. The position peaked at $15K in Q2 2014. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Trust Company of Vermont reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Trust Company of Vermont sold 85 Jazz Pharmaceuticals shares in Q2 2023, an estimated $12.4K.
Trust Company of Vermont first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Trust Company of Vermont's Jazz Pharmaceuticals position peaked at $15K in Q2 2014.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Trust Company of Vermont's 13F filing for Q2 2023, filed 17 Jul 2023.